<DOC>
	<DOC>NCT00273338</DOC>
	<brief_summary>The primary objective of this study is: - To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: - To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) - To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) - A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.</brief_summary>
	<brief_title>DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histopathologically or cytologically proven adenocarcinoma of the prostate Documented metastatic prostate adenocarcinoma Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging Age &gt;= 18 years Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2 Adequate hematologic, renal and hepatic function Life expectancy &gt;= 3 months Prior chemotherapy, except estramustine Prior chemotherapy with docetaxel Prior isotope therapy (e.g., strontium89, samarium153, etc.) One or more contraindications to the use of corticosteroids History of cancerrelated hypercalcemia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Androgen-independent Prostate Cancer (AIPC)</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>DN-101</keyword>
	<keyword>calcitriol</keyword>
	<keyword>Taxotere</keyword>
	<keyword>docetaxel</keyword>
</DOC>